Methylprednisolone in patients with membranous nephropathy and declining renal function

Area of Science:

• Nephrology
• Immunosuppressive Therapy

Background:

• Membranous nephropathy is a leading cause of nephrotic syndrome in adults.
• Progressive decline in renal function is a significant concern in membranous nephropathy.
• Limited effective treatment options exist for advanced stages of the disease.

Purpose of the Study:

• To evaluate the efficacy of high-dose corticosteroid therapy in patients with membranous nephropathy and deteriorating kidney function.
• To assess the impact of methylprednisolone and prednisolone on plasma creatinine levels and renal function.
• To determine the sustained benefit and potential reversal of treatment effects.

Main Methods:

• A cohort of 15 consecutive patients with membranous nephropathy and declining renal function were enrolled.
• Treatment involved intravenous methylprednisolone (1g daily for 5 days) followed by oral prednisolone.
• Plasma creatinine levels were monitored to assess changes in renal function.

Main Results:

• A mean reduction of 46% in plasma creatinine levels was observed.
• Sustained beneficial effects on renal function were noted in 10 out of 15 patients.
• Treatment reversal occurred in 3 patients by six months; 2 patients showed no improvement.

Conclusions:

• High-dose steroid therapy, specifically methylprednisolone and prednisolone, appears beneficial for many patients with membranous nephropathy and declining renal function.
• The intervention demonstrates potential for improving kidney function, though sustained efficacy varies.
• Further research is warranted to optimize treatment protocols and predict patient response.